Chino
Chino
Chino, California, United States26 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type | Dyskinesias, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Psychomotor Agitation, Psychomotor Disorders, Signs and Symptoms, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-10-08 | NCT06052254 | |
| A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201) | attention deficit hyperactivity disorder, inattentive type, neurodevelopmental disorder, oppositional defiant disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-10-07 | NCT07755410 | |
| A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN) | Schizophrenia Spectrum and Other Psychotic Disorders, psychiatric disorder, schizophrenia | Recruiting | Phase 3 | 2026-10-06 | NCT07288567 | |
| An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study) | anxiety disorder, depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Enrolling by invitation | Phase 2 | 2026-10-06 | NCT07161700 | |
| A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study) | anxiety disorder, depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-10-06 | NCT07065240 | |
| Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease | Alzheimer disease, Dyskinesias, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Psychomotor Agitation, Psychomotor Disorders, Signs and Symptoms, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 2 | 2026-10-06 | NCT06808984 | |
| ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response | Depressive Disorder, Treatment-Resistant, depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-10-05 | NCT07284667 | |
| Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | Psychosis Associated With Alzheimer's Disease | Recruiting | Phase 3 | 2026-09-29 | NCT05980949 | |
| Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia | Schizophrenia Spectrum and Other Psychotic Disorders, psychiatric disorder, schizophrenia | Recruiting | Phase 3 | 2026-09-28 | NCT07686263 | |
| A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD) | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-09-25 | NCT07621237 | |
| NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia | Schizophrenia Spectrum and Other Psychotic Disorders, psychiatric disorder, schizophrenia | Recruiting | Phase 3 | 2026-09-25 | NCT07114874 | |
| A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents | Schizophrenia Spectrum and Other Psychotic Disorders, autism, autism spectrum disorder, neurodevelopmental disorder, pervasive developmental disorder, psychiatric disorder, schizophrenia | Recruiting | Phase 3 | 2026-09-22 | NCT07424404 | |
| A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | Alzheimer disease, Psychotic Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 3 | 2026-09-22 | NCT06585787 | |
| A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor | Bipolar and Related Disorders, Dyskinesias, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Psychotic Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, Signs and Symptoms, bipolar disorder, central nervous system disorder, depressive disorder, drug-induced dyskinesia, major depressive disorder, mood disorder, movement disorder, nervous system disorder, psychiatric disorder, schizoaffective disorder, schizophrenia, tardive dyskinesia | Recruiting | Phase 4 | 2026-09-18 | NCT07105111 | |
| A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3) | Mania, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nervous system disorder | Recruiting | Phase 3 | 2026-09-14 | NCT06929273 | |
| A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. | Arterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Infarction, Lipid Metabolism Disorders, Necrosis, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, arteriosclerosis disorder, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, coronary artery disorder, coronary stenosis, heart disorder, hyperlipidemia, ischemic disease, metabolic disease, myocardial infarction, myocardial ischemia, nervous system disorder, stroke disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-09-04 | NCT05739383 | |
| Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | Arterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, hyperlipidemia, metabolic disease, vascular disorder | Active, not recruiting | Phase 3 | 2026-08-25 | NCT05030428 | |
| Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) | Schizophrenia Spectrum and Other Psychotic Disorders, psychiatric disorder, schizophrenia | Recruiting | Not stated | 2026-08-19 | NCT07379827 | |
| Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder | Mania, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, bipolar I disorder, nervous system disorder | Active, not recruiting | Phase 2 | 2026-08-10 | NCT07046494 | |
| NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-08-10 | NCT06963021 | |
| A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. | bipolar I disorder, depressive disorder | Recruiting | Phase 3 | 2026-07-27 | NCT04777357 | |
| Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol | Disorders of Excessive Somnolence, Dyssomnias, Sleep Disorders, Intrinsic, depressive disorder, major depressive disorder, mood disorder, nervous system disorder, psychiatric disorder, sleep-wake disorder | Recruiting | Phase 3 | 2026-07-24 | NCT07484217 | |
| A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5) | Alzheimer disease, Psychotic Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 3 | 2026-06-30 | NCT06947941 | |
| Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia | Dyskinesias, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, central nervous system disorder, drug-induced dyskinesia, movement disorder, nervous system disorder, tardive dyskinesia | Recruiting | Phase 2 | 2026-06-23 | NCT07365462 | |
| A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine | Bipolar and Related Disorders, Mania, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, bipolar disorder, mood disorder, nervous system disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-06-23 | NCT07140913 |